Milestone Pharmaceuticals
MIST
23 hedge funds and large institutions have $240M invested in Milestone Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.05% less ownership
Funds ownership: 53.41% → 53.37% (-0.05%)
8% less funds holding
Funds holding: 25 → 23 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
32% less capital invested
Capital invested by funds: $350M → $240M (-$111M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.12M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$714K |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$443K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.8K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$3.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.79M |
| 2 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$1.06M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$459K |
| 4 |
Millennium Management
New York
|
-$207K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$98.4K |
MIST Hedge Fund Activity: Q3 2019 in Review
23 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2019, worth a combined $240M — down 32% from $350M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MIST and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Adage Capital Partners, adding an estimated $5.12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $6.79M sold.
- 23 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2019, down from 25 in Q2 2019.
- Funds reported $240M of Milestone Pharmaceuticals stock for Q3 2019, down 32% quarter-over-quarter.
- 1 fund opened new Milestone Pharmaceuticals positions in Q3 2019 and 3 closed out, a net change of -2 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2019 was Adage Capital Partners, an estimated $5.12M added.
- The largest Milestone Pharmaceuticals seller in Q3 2019 was Farallon Capital Management, an estimated $6.79M sold.
Based on aggregated 13F filings for Q3 2019.